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Abstract
Herpes simplex encephalitis (HSE) is a life-threatening complication of herpes simplex
virus (HSV) infection. Acyclovir (ACV) is the antiviral treatment of choice, but may lead to
emergence of ACV-resistant (ACVR) HSV due to mutations in the viral UL23 gene encoding
for the ACV-targeted thymidine kinase (TK) protein. Here, we determined the prevalence of
intrathecal ACVR–associated HSV TK mutations in HSE patients and compared TK geno-
types of sequential HSV isolates in paired cerebrospinal fluid (CSF) and blister fluid of
mucosal HSV lesions. Clinical samples were obtained from 12 HSE patients, encompass-
ing 4 HSV type 1 (HSV-1) and 8 HSV-2 encephalitis patients. HSV DNA load was deter-
mined by real-time PCR and complete HSV TK gene sequences were obtained by nested
PCR followed by Sanger sequencing. All HSV-1 HSE patients contained viral TK mutations
encompassing 30 unique nucleotide and 13 distinct amino acid mutations. By contrast, a
total of 5 unique nucleotide and 4 distinct amino acid changes were detected in 7 of 8 HSV-
2 patients. Detected mutations were identified as natural polymorphisms located in non-
conserved HSV TK gene regions. ACV therapy did not induce the emergence of ACVR-
associated HSV TK mutations in consecutive CSF and mucocutaneous samples of 5 indi-
vidual patients. Phenotypic susceptibility analysis of these mucocutaneous HSV isolates
demonstrated ACV-sensitive virus in 2 HSV-1 HSE patients, whereas in two HSV-2 HSE
patients ACVR virus was detected in the absence of known ACVR-associated TK mutations.
In conclusion, we did not detect intrathecal ACVR-associated TK mutations in HSV isolates
obtained from 12 HSE patients.
Introduction
Herpes simplex encephalitis (HSE) is a rare life-threatening complication of infection with her-
pes simplex virus type 1 (HSV-1) and HSV-2. HSE affects 1 in 250,000 to 500,000 persons per
year in the USA and comprises about one-fifth of all encephalitis cases in the UK [1,2]. HSV-1
causes 90% of HSE cases in immunocompetent adults, whereas HSV-2-associated HSE is more
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common in neonates and immunocompromised individuals [2,3]. Prompt diagnosis, based on
magnetic resonance imaging of the brain and detection of HSV DNA in cerebrospinal fluid
(CSF) by PCR, and preemptive administration of antiviral drugs are pivotal to reduce HSE-
induced morbidity and mortality [2–4]. Mortality from HSE is about 70% in untreated
patients, which is reduced to 11% to 19% when immediate antiviral therapy is provided [1,5].
Nevertheless, approximately 12% to 60% of treated HSE patients develop neurological sequelae
[1,5].
Treatment of choice is intravenous administration of the antiviral agent acyclovir (ACV), a
highly selective drug for human alphaherpesviruses with limited side effects [6,7]. ACV is a
prodrug converted by the viral thymidine kinase (TK) protein to ACV-monophosphate, which
is subsequently converted by cellular kinases to the active compound ACV-triphosphate that
inhibits HSV DNA replication [8]. ACV resistant (ACVR) HSV is found in less than 1% of
immunocompetent, but more frequently in immunocompromised individuals (4% to 30%)
and in infected immunoprivileged organs including the cornea [8–11]. Over 95% of ACVR
HSV are caused by mutations in the viral UL23 gene encoding the ACV-targeted TK protein,
while mutations in the viral UL30 DNA polymerase gene account for the remaining 5% [12].
Few studies reported on ACV treatment refractory HSE cases due to infection with ACVR
HSV, but the overall prevalence of intrathecal ACVR HSV in a clinically unbiased cohort of
patients with either HSV-1 or HSV-2-induced HSE has not been described [13–16]. Further-
more, the highly polymorphic nature of the HSV-1 UL23 TK gene, and to a lesser account its
HSV-2 counterpart, facilitates genetic differentiation of HSV isolates [10,17,18].
The aim of this study was twofold. First, to determine the prevalence of intrathecal ACVR
HSV in a cohort of 4 HSV-1 and 8 HSV-2 HSE patients. Second, to compare the HSV TK
genotype variation of sequential CSF and/or blister fluid samples (BLS) obtained from the
same patient during the course of disease.
Materials and Methods
Clinical specimens
Surplus CSF samples of suspected HSE patients, obtained for diagnostic purposes at the Eras-
mus Medical Center (Rotterdam, the Netherlands), were collected between 2001 to 2012. A
total of 15 CSF samples from 12 HSE patients were included: HSV-1 (n = 4) and HSV-2 (n = 8)
(Table 1). Additionally, paired BLS from mucocutaneous lesions of two HSV-1 (patients #3
and #4) and two HSV-2 HSE patients (patients #10 and #11) were obtained. According to our
institutional “Opt-Out” system, which is defined by the National "Code of Good Conduct"
(Dutch: Code Goed Gebruik, May 2011) [19], surplus clinical materials are made available for
research purposes if the patient has not objected. Specifically, patients/donors or caretakers
that object are registered and their specimens are excluded from future research. Accordingly,
the current study used only surplus clinical samples from HSE patients that did not object use
of their surplus clinical samples for future research purposes. The study protocol was approved
by the medical ethical committee of the Erasmus MC (MEC-2012-226) and informed consent
was waived. The study was performed according to the tenets of the Helsinki declaration.
DNA extraction and quantitative real-time PCR
DNA was extracted from CSF and BLS samples using the QIAamp DNAMini Kit (Qiagen)
according to manufacturer’s instructions. Quantitative PCR (qPCR) for HSV was performed
using an ABI Prism 7500 Real-Time PCR System and TaqMan Universal PCR Master Mix
(Life Technologies) with primers and probes specific for HSV-1 and HSV-2 as described before
[20]. Electron microscopy quantified high-titer HSV stocks (Advanced Biotechnologies
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Incorporated) were used for standardization of qPCR assays [20]. The lower limit of detection
was 50 HSV genome equivalent copies per mL.
HSV TK gene sequencing
The entire HSV-1 and HSV-2 TK genes (both 1,131 bp long) were amplified from DNA
extracted from clinical specimens by nested PCR using PfuUltra II Fusion HS DNA Polymer-
ase (Stratagene), 5% dimethyl sulfoxide (Sigma-Aldrich) and the following primers at the indi-
cated concentrations: HSV-1 external forward 5’-GCGGTCCCAGGTCCACTTC-3’ (1.2 μM),
HSV-1 external reverse 5’-cacccgtgcgttttattctgtc-3’ (1.2 μM), HSV-1 nested forward 5’-atcttgg
tggcgtgaaactcc-3’ (0.4 μM), HSV-1 nested reverse 5’-ggttccttccggtattgtctcc-3’ (0.4 μM), HSV-2
external forward 5’-gtcagcagcgttccacaaatcc-3’ (0.6 μM), HSV-2 external reverse 5’-ggggtggggtg
agggtaaaag-3’ (0.6 μM), HSV-2 nested forward 5’-cgttgaactcccgcacctctc-3’ (0.4 μM) and HSV-2
nested reverse 5’-cccccgcgcttatggacac-3’ (0.4 μM) (all from Eurogentec) [10]. First round
amplification conditions included denaturation for 2 min at 95°C, followed by 40 cycles 30 s at
95°C, 25 s at 62°C, 40 s at 72°C and a final elongation of 3 min at 72°C. Nested PCR was per-
formed, using 1 μl of the first PCR reaction, for 35 cycles using identical conditions. The result-
ing TK amplicons were purified from agarose gel using the MiniElute Gel Extraction Kit (Qiag
en) and sequenced on the ABI Prism 3130 XL Genetic Analyzer with the BigDye v3.1 Cycle
Sequencing Kit (both Applied Biosciences), the above-mentioned nested primers, and the fol-
lowing additional internal primers at the indicated concentrations: HSV-1 internal forward
5'-CGCCCAGATAACAATGGGC-3' (1 μM), HSV-1 internal reverse 5'-CCCATAAACGCGG
Table 1. Demographics and clinical characteristics of herpes simplex encephalitis patients.
Patient Virusa Age,
Sexb
Immune
statusc
Time onset–
first CSFd
Time onset–AV
therapye
AV therapy (duration in
days)f
Follow-up
(months)
Clinical outcome at
end of follow-upg
1 HSV-1 51, F - 11 months None None 142 Moderate disability
2 HSV-1 35, M + 4 days 4 days ACV iv (14); GCV iv (28) 18 Complete recovery
3 HSV-1 64, F + 3 days 5 days ACV iv (14); ACV oral
(7)
1 Complete recovery
4 HSV-1 47, M - 14 days 10 days ACV iv (±14–21) 114 Severe disability
5 HSV-2 59, M - 21 days 22 days ACV iv (10) 24 Complete recovery
6 HSV-2 36, F + 4 days 4 days ACV iv (±14–21) Unknown Unknown
7 HSV-2 19, F + 1 day 3 days ValGCV oral (12 days) 7 Complete recovery
8 HSV-2 49, F + 1 day 1 day ValACV oral (14) 38 Moderate disability
9 HSV-2 61, M - 10 days 10 days ACV iv (28); ValACV
oral (21)
18 Good recovery
10 HSV-2 28, M - 5 days 5 days ACV iv (14) 108 Complete recovery
11 HSV-2 35, M - ± 2 months 14 days ACV iv (2); none (32);
ValACV oral (39)
3 Good recovery
12 HSV-2 61, M - 8 days 3 days ACV iv (19) 3 Good recovery
a Causative virus.
b Age in years. F: female; M: male.
c +: immunocompetent;—: immunocompromised.
d Time interval between the onset of clinical symptoms and time of (first) cerebrospinal fluid (CSF) sample.
e Time interval between the onset of clinical symptoms and the onset of antiviral (AV) therapy.
f Successive antiviral therapies and routes of administration are indicated. ACV: acyclovir; GCV: ganciclovir; ValACV: valacyclovir; ValGCV: valganciclovir;
iv: intravenous.
g Complete recovery: no adverse events; other outcome criteria classified according to Glasgow outcome scale [22].
doi:10.1371/journal.pone.0155531.t001
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CGAATCG-3' (1 μM), HSV-2 internal forward 5'-accaggttcgtgccgggcgcggtc-3' (1 μM) and
HSV-2 internal reverse 5'-tatcgcctccctgctgtgctaccc-3'(1 μM), as described [10,21]. TK
sequences were aligned to consensus TK sequences of the HSV-1 reference strain 17 (GenBank
accession number: JN555585.1) and HSV-2 reference strain HG52 (NCBI accession number:
NC_001798.1) using Lasergene 10.1 (DNASTAR). Obtained HSV-1 and HSV-2 TK sequences
were deposited in GenBank under the accession numbers KT266758 –KT266777.
Phenotypic ACV susceptibility of HSV isolates
Phenotypic ACV susceptibilities of herpes simplex virus isolates were determined by plaque
reduction assay according to the Clinical and Laboratory Standards Institute’s guidelines. In
brief, confluent monolayers of Vero cells cultured in 12-well plates were infected with 50–100
plaque forming units HSV per well for 75 min at 36.5°C in a CO2 incubator. Inoculum was
removed and EMEM containing 0.8% agarose (both Lonza) and 0–64 mg/mL ACV (GlaxoS-
mithKline) was added. Plates were incubated at 36.5°C with 5% CO2 for 72 hours, fixed using
10% formalin and stained with crystal violet. Plaques were counted using a light microscope.
HSV reference strains HSV-1 F and HSV-2 HG52 were included as ACV-sensitive controls.
GraphPad Prism 5 was used to calculate the half maximum (50%) inhibitory concentrations
(IC50) of ACV from the dose response curves using the log(inhibitor) versus normalized
response with a variable Hill slope. Experiments were performed in duplicate and three inde-
pendent experiments were performed. HSV isolates were considered ACVR if the mean IC50
was equal or greater than five times the IC50 value of the sensitive control HSV-1 or HSV-2
strains.
Results
Demographics and clinical characteristics of HSE patients
Fifteen CSF samples were obtained from 12 HSE patients comprising 4 HSV-1 and 8 HSV-2
HSE cases (Table 1). Five of 12 (42%) of patients were female, the overall median age at time of
the first CSF sample was 48 years (range: 19–64 years) and 7 of 12 patients (58%) were immu-
nocompromised. Age, gender and immune status distribution were comparable between HSV-
1 and HSV-2 HSE patients. Median time interval between onset of disease and first CSF sample
was 6.5 days (range: 1 day– 11 months). Eleven of 12 patients (92%) received antiviral therapy,
starting at a median time interval of 5 days (range: 1–22 days) after onset of disease symptoms.
Patient #1 did not receive antiviral therapy because she was initially suspected of and treated
for tuberculous meningoencephalitis; HSV-1 DNA was detected in CSF at 11 months after
onset of neurological disease. The median follow-up was 18 months (range: 1 month– 11
years); one patient was lost to follow-up. Five of 11 patients (45%) showed complete recovery,
3 of 11 patients (27%) showed good recovery, 2 of 11 (18%) patients showed moderate disabili-
ties and 1 patient developed severe disabilities according to the Glasgow outcome scale [22].
Prevalence of ACVR HSV in CSF from HSE patients
To determine the prevalence of intrathecal ACVR HSV in the cohort of clinically unbiased
HSV-1 (n = 4) and HSV-2 (n = 8) HSE patients, DNA was isolated from surplus CSF and sub-
sequently used to amplify the complete viral TK gene by nested PCR followed by Sanger
sequencing. Median HSV-1 and HSV-2 DNA loads in the primary CSF samples of the HSE
patients were 3.7 x 104 copies/mL (range<50–1.3 x 106 copies/mL) and 1.8 x 104 copies/mL
(range 5.0x102–2.2x105 copies/mL), respectively (Table 2). HSV-1 and HSV-2 TK sequences
were obtained from all CSF samples analyzed, irrespective of viral DNA load. Among HSV-1
Acyclovir Resistance in HSV Encephalitis Patients
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HSE patients, all CSF samples had viral TK mutations comprising 30 unique nucleotide and 13
distinct amino acid substitutions compared to HSV-1 reference strain 17 (Table 2). By contrast,
TK sequences in 7 of 8 (88%) CSF samples from HSV-2 HSE patients contained mutations,
encompassing only 5 unique nucleotide and 4 distinct amino acid substitutions compared to
HSV-2 reference strain HG52.
To predict the impact of the detected mutations on TK function, we determined their loca-
tion with respect to highly conserved and functional domains of HSV-1 and HSV-2 TK (Fig 1).
Except for the D286E mutation in HSV-1 TK protein of patient #4, all amino acid substitutions
were located in non-conserved TK domains. All HSV-2 TK and 11 of 13 (85%) HSV-1 TK
amino acid substitutions were previously defined as natural polymorphisms resulting in an
ACV sensitive (ACVS) HSV phenotype [10–12, 23–27]. The HSV-1 TK isolate from patient #4
contained the R41H mutation, previously described as natural polymorphism but also as
ACVR-associated mutation [10,12,28–30]. One new non-synonymous mutation (C689T) was
identified in CSF of HSV-1 HSE patient #2 resulting in the exchange of the nonpolar neutral
amino acid alanine at position 230 with a similar nonpolar neutral amino acid valine (Table 2).
Collectively, the data indicate that the prevalence of intrathecal ACVR-associated TK muta-
tions in HSV-1 and HSV-2 in HSE patients is low.
Genetic characterization of HSV TK in sequential virus isolates of
individual HSE patients
Besides the causative role of TK mutations in the viral ACV susceptibility phenotype, the vari-
ability of the TK provides insight into the clonal composition of an HSV-1 isolate [10,17,18].
From 4 HSE patients multiple CSF, and/or BLS from oral HSV-1 or anal HSV-2 mucosal
lesions were obtained during the same HSE episode (patients #3, #4, #9, and #11). Additionally,
we examined one HSV-2 HSE patient (patient #10) who experienced a genital herpes episode
about 4.5 months after HSE (Table 2). To compare TK genotype variation in HSV isolates
from concurrent or consecutive HSE and mucosal HSV infections, we sequenced the TK genes
of HSV DNA obtained from multiple BLS and CSF samples of the same HSE patient (Table 2).
TK sequences were identical for all sequential isolates of individual patients, including those
from distinct anatomical HSV infection sites, suggesting potential involvement of the same
HSV strain per time and anatomical site.
Because HSV isolates consist of mixtures of ACVS and ACVR variants [8–11], ACV therapy
may select for ACVR variants; particularly in immunocompromised individuals and in immu-
noprivileged organs such as the eye and brain [8–11]. To determine the effect of ACV treat-
ment on the appearance of ACVR HSV in HSE patients, we analyzed viral TK sequences in 3
consecutive CSF samples obtained from two HSE patients during ACV treatment (patients #3
and #9; Table 2). Whereas ACV treatment reduced intrathecal HSV DNA loads, emergence of
ACVR-associated TK mutations in intrathecal HSV could not be detected (Tables 1 and 2).
Likewise, we did not detect ACVR-associated mutations in HSV TK of CSF samples obtained
at 4 and 40 days after onset of ACV therapy (patients #4 and #11, respectively). Thus, short-
term ACV therapy did not select for detectable intrathecal ACVR-associated mutations in HSV
TK in these 4 HSE patients.
Phenotypic ACV susceptibility of HSV isolates from HSE patients
Next we aimed to phenotypically characterize the ACV susceptibility of HSE isolates from HSE
patients. HSV was isolated from BLS of oral HSV-1 and anal HSV-2 mucosal lesions (Tables 2
and 3), but could not be recovered from CSF due to the low viral loads and/or limited volume
of residual sample. These findings are in accordance with the low success rate in recovering
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culturable HSV from CSF samples (<4%) obtained from HSE patients [33, 34]. As outlined
above, TK genotypes were identical in CSF and BLS samples from patients #3, #4, #10 and #11
(Table 2). HSV-1 isolates from patients #3 and #4, the latter containing the disputed R41H TK
mutation, were not ACVR (Table 3). By contrast, HSV-2 BLS isolates from patient #10 and #11
obtained at 132 and 34 days after onset of ACV therapy were found to be ACVR in the absence
of ACVR-associated TK mutations (Table 3 and Fig 1), suggesting involvement of additional
mutations in the viral DNA polymerase gene.
Table 2. Viral thymidine kinase polymorphisms in clinical samples obtained from herpes simplex encephalitis patients.
Herpes simplex virus (HSV) thymidine kinase (TK) gene
Time interval
Patient Virusa Clinical
Sampleb
First CSF- samplec Onset AV
therapy—
sampled
Viral load
(gec/mL)e
Nucleotide polymorphismsf Amino acid polymorphismsg
1 HSV-1 CSF NA NA <5.0 x101 A106G, C171T, G266A, T271C, T717C, G793A,
C892T, T933C and C1056T
K36E, R89Q and A265T
2 HSV-1 CSF NA 0 7.9 x 103 A68G, G102A, A106G, C171T, G266A, T271C,
C513T, C689T, T717C, G719A, G793A, T933C and
A1065C
N23S, K36E, R89Q, A230V,
G240E and A265T
3 HSV-1 CSF1 NA -2 1.3 x 106 A106G, C171T, G266A, T271C, T717C, G793A,
C892T, T933C and C1056T
K36E, R89Q and A265T
BLS 2 0 1.4 x 104 Identical to CSF1 Identical to CSF1
CSF2 3 1 3.5 x 105 Identical to CSF1 Identical to CSF1
CSF3 10 8 4.4 x 103 Identical to CSF1 Identical to CSF1
4 HSV-1 BLS1 -4 0 8.0 x 106 T16G, A24G, A68G, A106G, G122A, C171T,
T271C, A528G, C575T, C672T, T717C, G723A,
G751T, G793A, G799T, C802A, C858A, T915C,
T933C, C1053T and A1126C
N23S, K36E, R41H, A192V,
G251C, A265T, V267L, P268T,
D286E and N376H
BLS2 -1 3 3.8 x 107 Identical to BLS1 Identical to BLS1
CSF NA 4 6.6 x 104 Identical to BLS1 Identical to BLS1
5 HSV-2 CSF NA -1 2.2 x 105 G116A G39E
6 HSV-2 CSF NA 0 1.2 x 104 G116A, A232G, G420T and C852T G39E, N78D and L140F
7 HSV-2 CSF NA -2 2.3 x 104 None None
8 HSV-2 CSF NA 0 1.0 x 103 G116A G39E
9 HSV-2 CSF1 NA 0 7.2 x 104 G116A G39E
CSF2 9 9 3.9 x 103 Identical to CSF1 Identical to CSF1
10 HSV-2 CSF NA 0 2.1 x 105 G116A G39E
BLS 132 132 1.3 x 105 Identical to CSF Identical to CSF
11 HSV-2 BLS -6 34 1.9 x 107 G116A and A752G G39E and Q251R
CSF NA 40 5.9 x 103 Identical to BLS Identical to BLS
12 HSV-2 CSF NA 5 4.9 x 102 G116A G39E
a Causative virus.
b Sample type. CSF: cerebrospinal fluid; BLS: blister swab.
c Time interval (days) between the time point of first CSF sample and acquisition of the indicated sample. NA, not applicable.
d Time interval (days) between the start of antiviral (AV) treatment and the time of sampling. NA, not applicable. Values <0: sample obtained prior to onset
AV therapy; Value = 0: AV therapy started on the day of sampling; Values >0: sample obtained after onset of AV therapy.
e HSV genome equivalent copies per mL (gec/mL).
f TK DNA sequences were compared to reference HSV-1 TK (strain 17; GenBank accession number JN555585.1) and HSV-2 TK (strain HG52; NCBI
accession number NC_001798.1) sequences. Regular font: natural non-synonymous polymorphisms; italics: natural synonymous polymorphisms; bold:
new mutation; bold and underlined: mutation with unclear significance for ACV resistance.
g Predicted TK protein sequences were compared to to reference HSV-1 TK (strain 17; GenBank accession number JN555585.1) and HSV-2 TK (strain
HG52; NCBI accession number NC_001798.1) sequences. Regular font: natural polymorphisms; bold: new mutation; bold and underlined: mutation with
unclear significance for ACV resistance.
doi:10.1371/journal.pone.0155531.t002
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Discussion
Preemptive intravenous ACV therapy has reduced morbidity and mortality in clinically sus-
pected HSE patients [5–7]. Although ACV therapy refractory HSE case reports with intrathecal
ACVR HSV have been described [13–16], the prevalence of intrathecal ACVR HSV-1 and
HSV-2 in HSE patients is unknown. The current study showed that intrathecal ACVR-associ-
ated HSV TK mutations are uncommon in a cohort of clinically unbiased HSV-1 (n = 4) and
HSV-2 (n = 8) HSE patients and do not appear to develop intrathecally.
Synonymous and non-synonymous mutations were detected in the HSV TK gene from 11
of 12 (92%) HSE patients, most of which were located outside the conserved regions of TK and
have been described as natural polymorphisms [10–12, 23–27]. Patient #4 contained the
D286E mutation located within the C-terminal conserved domain of HSV-1 TK (amino acid
284–289). This mutation was previously reported as natural polymorphism [10, 12, 23, 25, 26],
which did not confer phenotypic ACVR in the BLS HSV-1 isolate of patient #4, possibly
because this mutation replaces the negatively charged amino acid aspartic acid with a similarly
charged glutamic acid. CSF and BLS of patient #4 contained an HSV-1 isolate harboring the
R41H TK mutation. This mutation has been identified in an intrathecal ACVR HSV-1 isolate
from an HSE patient refractory to ACV therapy [16] and we have previously shown that a
recombinant HSV-1 TK protein containing R41H did not convert ACV to ACV-monophos-
phate in vitro [30]. By contrast, the R41H TK in the HSV-1 isolate from patient #4 did not con-
fer ACV resistance (Table 3) corroborating previous reports describing this mutation as
natural polymorphism [12,26,28]. The HSV-1 isolate from patient #2 contained a new muta-
tion (A230V) located in the non-conserved region of HSV-1 TK (Fig 1) that is unlikely to affect
TK function, although this needs to be experimentally verified in functional TK assays
[18,35,36].
Consistent with previous studies our data indicate a higher prevalence of polymorphisms in
the TK gene of HSV-1 compared to HSV-2 [12,21,37]. The genetic variability of the HSV-2
Fig 1. Location of identified amino acid substitutions in HSV thymidine kinase. Schematic representation of all identified amino acid substitutions in the
thymidine kinase (TK) proteins of intrathecal HSV-1 (A) and HSV-2 (B) isolates obtained from herpes simplex encephalitis patients. Note that except for the
D286Emutation in HSV-1 all amino acid substitutions are located outside of the functional domains of TK. Grey boxes depict highly conserved and functional
domains, i.e. ATP-binding site (ATP), nucleotide binding sites (NBS) and a cysteine residue at position 336 and 337 for HSV-1 and HSV-2, respectively [31,
32]. TK amino acid locations are indicated according to HSV-1 reference strain 17 (GenBank accession number: JN555585.1) and HSV-2 reference strain
HG52 (NCBI accession number: NC_001798.1). Regular font: natural polymorphisms; bold: newmutation; bold and underlined: mutation with unclear
significance for ACV resistance.
doi:10.1371/journal.pone.0155531.g001
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DNA polymerase gene exceeds that of the TK gene [38], suggesting a more prominent role of
DNA polymerase mutations in the acquisition of ACVR in HSV-2 isolates. Notably, 2 HSV-2
BLS isolates obtained at 34 and 132 days after onset of ACV therapy from 2 immunocompro-
mised patients (#10 and #11) were found to be phenotypically ACVR in the absence of known
ACVR-associated TK mutations, suggestive of accompanying mutations in the viral DNA poly-
merase gene [12]. Alternatively, the isolate’s ACVR phenotype may be caused by G39E (patient
#10) or G39E & Q251R (patient #11) HSV-2 TK polymorphisms in combination with muta-
tions in genes encoding additional components of the viral DNA replication machinery:UL5,
UL8, UL9, UL29, UL42 or UL52 [38, 39]. Interestingly, HSV ACVR did not affect clinical out-
come in these 2 patients (Table 1). Overall, the data suggests that combined sequence analysis
of viral TK and DNA polymerase genes is needed to determine the prevalence of ACVR in CSF
samples of HSE patients in future studies.
Previous studies showed that ACV therapy was not associated with an increased risk for the
emergence of ACVR HSV-1 in immunocompetent patients [40,41], supporting the currently
recommended 14 to 21 days of intravenous ACV treatment of HSE patients [5,42]. The current
study showed that HSV TK polymorphisms were present in CSF of 9 patients prior to the
onset of ACV therapy. Furthermore, short-term ACV therapy (median: 8 days; range: 1–40
days) did not induce the emergence of ACVR-associated TK mutations in HSV isolates
obtained from CSF samples of 4 HSE patients (Table 2). However, HSV clinical isolates are
quasispecies composed of genetically related ACVS and ACVR variants [10,21,43]. The relative
abundance of ACVS and ACVR HSV determines the isolate’s susceptibility to ACV [10,43,44].
Due to limited quantities of HSV DNA recovered from rare CSF samples, we applied pool
sequencing to determine the TK sequence of the major HSV isolate present in CSF or mucocu-
taneous samples. Whereas this reflects the responsiveness of HSE patients to ACV therapy,
deep sequencing of HSV TK in future studies should provide more insight into the anticipated
subtle emergence of intrathecal ACVR viruses in response to short-term ACV treatment of
HSE patients.
Table 3. Acyclovir susceptibility of HSV isolates obtained frommucocutaneous samples of herpes simplex encephalitis patients.
Patient Virusa Sampleb Amino acid polymorphismsc Mean [± SD] IC50 of ACV
(μM)d
ACV
susceptibilitye
3 HSV-1 BLS K36E, R89Q and A265T 0.34 [± 0.05] Sensitive
4 HSV-1 BLS1 N23S, K36E, R41H, A192V, G251C, A265T, V267L, P268T, D286E
and N376H
3.50 [± 0.55] Sensitive
BLS2 Identical to BLS1 2.85f Sensitive
10 HSV-2 BLS G39E 14.27 [± 1.52] Resistant
11 HSV-2 BLS G39E and Q251R 20.17 [± 6.73] Resistant
a Causative virus.
b Sample type. BLS: blister swab.
c Predicted TK protein sequences were compared to to reference HSV-1 TK (strain 17; GenBank accession number JN555585.1) and HSV-2 TK (strain
HG52; NCBI accession number NC_001798.1) sequences. Regular font: natural polymorphisms; bold: new mutation; bold and underlined: mutation with
unclear significance for ACV resistance.
d Mean half maximum (50%) inhibitory concentration (IC50) value of ACV ± standard deviation (SD) for the indicated isolates (n = 3 experiments). Mean
IC50 value for the sensitive control strains HSV-1 F and HSV-2 HG52 were 1.11 μM and 1.93 μM, respectively.
e Isolates were designated as “Sensitive” or “Resistant” based on the ACV IC50 values. Cut-off value for ACV resistance was defined as 5 times the
mean IC50 value of HSV-1 F strain (5.55 μM) and HSV-2 HG52 strain (9.65 μM).
f IC50 value represents mean of duplicate wells from a single experiment.
doi:10.1371/journal.pone.0155531.t003
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In addition to its role in ACVR, the genetic variability of the viral UL23 TK gene facilitates
discrimination between HSV-1 strains [10,17,18,30]. We have shown that identical TK
sequences were recovered from successive CSF samples and samples from distinct anatomical
sites (i.e. CSF and BLS from herpetic oral or genital lesions), suggesting that consecutive HSE
and mucosal HSV infections within the same individual could be caused by the same isolate.
However, given the low genetic variability of HSV-2 TK, sequence analysis of HSV US4, US7
and US8 genes, commonly used to genotype HSV isolates [45, 46], in addition to TK sequenc-
ing in future studies may provide additional insight into the intra-individual HSV-1 and, espe-
cially, HSV-2 strain diversity.
In conclusion, we did not detect intrathecal ACVR-associated TK mutations in HSV isolates
from HSE patients and short-term ACV therapy did not induce emergence of detectable
ACVR-associated TK mutations. Given the low genetic variability in the TK gene of HSV-2
compared to HSV-1, combined sequence analysis of HSV TK and DNA polymerase genes is
needed to conclusively determine the prevalence of ACVR HSV in HSE patients in future
studies.
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